Cargando…

Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial

BACKGROUND: Eptinezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody approved for the preventive treatment of migraine. In the phase 3 RELIEF study, eptinezumab resulted in shorter time to headache pain freedom and time to absence of most bothersome symptom (MBS; including n...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ailani, Jessica, McAllister, Peter, Winner, Paul K., Chakhava, George, Krog Josiassen, Mette, Lindsten, Annika, Sperling, Bjørn, Ettrup, Anders, Cady, Roger
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9164335/ https://www.ncbi.nlm.nih.gov/pubmed/35659622 http://dx.doi.org/10.1186/s12883-022-02714-1

Ejemplares similares

Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
por: Ailani, Jessica, et al.
Publicado: (2023)

Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study
por: McAllister, Peter, et al.
Publicado: (2022)

Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study
por: Cady, Roger, et al.
Publicado: (2022)

Reduction in migraine-associated burden after eptinezumab treatment in patients with chronic migraine
por: McAllister, Peter, et al.
Publicado: (2022)

Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial
por: Ashina, Messoud, et al.
Publicado: (2023)

Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study
por: Barbanti, Piero, et al.
Publicado: (2022)

Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
por: Smith, Timothy R., et al.
Publicado: (2021)

Eptinezumab for migraine prevention in patients 50 years or older
por: Martin, Vincent, et al.
Publicado: (2022)

Efficacy and safety of eptinezumab in patients with migraine and self-reported aura: Post hoc analysis of PROMISE-1 and PROMISE-2
por: Ashina, Messoud, et al.
Publicado: (2022)

Correction to: Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
por: Smith, Timothy R., et al.
Publicado: (2021)

Long-term reductions in disease impact in patients with chronic migraine following preventive treatment with eptinezumab
por: Blumenfeld, Andrew, et al.
Publicado: (2022)

Eptinezumab for migraine
Publicado: (2022)

Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies
por: Smith, Timothy R., et al.
Publicado: (2021)

Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies
por: Pozo-Rosich, Patricia, et al.
Publicado: (2022)

Early response to eptinezumab indicates high likelihood of continued response in patients with chronic migraine
por: Buse, Dawn C., et al.
Publicado: (2022)

Progress in the Treatment of Migraine Attacks: From Traditional Approaches to Eptinezumab
por: Scuteri, Damiana, et al.
Publicado: (2021)

Patient‐identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient‐centered outcome
por: Lipton, Richard B., et al.
Publicado: (2021)

Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2
por: Lipton, Richard B., et al.
Publicado: (2020)

A Review of Eptinezumab Use in Migraine
por: Datta, Abhigyan, et al.
Publicado: (2021)

Managing Migraine: Medication Overuse Headache and Treatment with Eptinezumab
por: Limberg, Nicole
Publicado: (2023)

Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
por: Ashina, Messoud, et al.
Publicado: (2020)

Eptinezumab Demonstrated Efficacy in Sustained Prevention of Episodic and Chronic Migraine Beginning on Day 1 After Dosing
por: Dodick, David W., et al.
Publicado: (2020)

Preventive migraine treatment with eptinezumab reduced acute headache medication and headache frequency to below diagnostic thresholds in patients with chronic migraine and medication‐overuse headache
por: Marmura, Michael J., et al.
Publicado: (2021)

Population pharmacokinetic and exposure‐response analysis of eptinezumab in the treatment of episodic and chronic migraine
por: Baker, Brian, et al.
Publicado: (2020)

Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial
por: Kudrow, David, et al.
Publicado: (2021)

Quantity changes in acute headache medication use among patients with chronic migraine treated with eptinezumab: subanalysis of the PROMISE-2 study
por: Cowan, Robert P., et al.
Publicado: (2022)

Eptinezumab: A calcitonin gene-related peptide monoclonal antibody infusion for migraine prevention
por: Morgan, Kelsey Woods, et al.
Publicado: (2021)

Effectiveness and Safety of Eptinezumab in Episodic and Chronic Migraine Headache in the UAE: A Retrospective Study
por: Bader, Yazan, et al.
Publicado: (2023)

Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review
por: Altamura, Claudia, et al.
Publicado: (2023)

Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy–2) study
por: Silberstein, Stephen, et al.
Publicado: (2020)

Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine
por: Pederson, Susan, et al.
Publicado: (2021)

The influence of weather on migraine – are migraine attacks predictable?
por: Hoffmann, Jan, et al.
Publicado: (2015)

Patient preference for early onset of efficacy of preventive migraine treatments
por: Ailani, Jessica, et al.
Publicado: (2022)

Are Menstrual and Nonmenstrual Migraine Attacks Different?
por: Vetvik, Kjersti Grøtta, et al.
Publicado: (2011)

Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo‐controlled randomized clinical trials
por: Schim, Jack D., et al.
Publicado: (2022)

Different dosage regimens of Eptinezumab for the treatment of migraine: a meta-analysis from randomized controlled trials
por: Yan, Zeya, et al.
Publicado: (2021)

Measuring dose-related efficacy of eptinezumab for migraine prevention: post hoc analysis of PROMISE-1 and PROMISE-2
por: Apelian, Rami, et al.
Publicado: (2022)

Migraine attacks the Basal Ganglia
por: Maleki, Nasim, et al.
Publicado: (2011)

Migraine attacks are of peripheral origin: the debate goes on
por: Do, Thien Phu, et al.
Publicado: (2023)

Imaging the premonitory phase of migraine - new insights into generation of the migraine attack
por: Maniyar, FH, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_hv7c0udspoeffiuhjhud4vd3o5